Type 2 diabetes mellitus in chronic hepatitis C virus infection: Risk factor or consequence?

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 4, 2013, Pages 295-297

  Abenavoli, Ludovico ^a   Rouabhia, Samir ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b University Hospital Center Touhami Benflis Algeria   (Algeria)

Author keywords

diabetes mellitus; hepatitis C virus; insulin resistance; risk factor

Indexed keywords

INSULIN; METFORMIN; PEGINTERFERON ALPHA; PIOGLITAZONE; PLACEBO; RIBAVIRIN; TELAPREVIR;

CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FATTY LIVER; GENOTYPE; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; LYMPHOPROLIFERATIVE DISEASE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PREVALENCE; REVIEW; RISK FACTOR;

ANTIVIRAL AGENTS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; HEPATITIS C, CHRONIC; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84877278814     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.13.13     Document Type: Review

References (20)

1. Cornberg M, Razavi HA, Alberti A et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 31(Suppl. 2), 30-60 (2011).
2. Himoto T, Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin. Dev. Immunol. 2012, 871401 (2012).
3. Abenavoli L, Almasio PL. Chronic hepatitis C infection and insulin resistance: two best friends. Expert Rev. Anti. Infect. Ther. 9(8), 555-558 (2011).
4. Rouabhia S, Malek R, Bounecer H et al. Prevalence of Type 2 diabetes in Algerian patients with hepatitis C virus infection. World J. Gastroenterol. 16(27), 3427-3431 (2010).
5. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J. Gastroenterol. 12(42), 6756-6765 (2006).
6. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J. Hepatol. 49(5), 831-844 (2008).
7. Arrese M, Riquelme A, Soza A. Insulin resistance, hepatic steatosis and hepatitis C: a complex relationship with relevant clinical implications. Ann. Hepatol. 9(Suppl.), 112-118 (2010).
8. Petta S, Cammà C, Di Marco V et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int. 31(4), 507-515 (2011).
9. Leandro G, Mangia A, Hui J et al.; HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130(6), 1636-1642 (2006).
10. Eslam M, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Use of HOMA-IR in hepatitis C. J. Viral Hepat. 18(10), 675-684 (2011).
11. Brenner DA, Kisseleva T, Scholten D et al. Origin of myofibroblasts in liver fibrosis. Fibrogenesis Tissue Repair 5(Suppl. 1), S17 (2012).
12. Negro F. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. J. Viral Hepat. 19(Suppl. 1), 42-47 (2012).
13. Sanyal AJ. Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. Liver Int. 31(Suppl. 1), 23-28 (2011).
14. Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon α-2a plus ribavirin. Hepatology 56(2), 464-473 (2012).
15. Walsh MJ, Jonsson JR, Richardson MM et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 55(4), 529-535 (2006).
16. Miyaaki H, Ichikawa T, Nakao K et al. Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C. Hepatol. Res. 39(9), 850-855 (2009).
17. Khattab M, Emad M, Abdelaleem A et al. Pioglitazone improves virological response to peginterferon α-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int. 30(3), 447-454 (2010).
18. Chojkier M, Elkhayat H, Sabry D, Donohue M, Buck M. Pioglitazone decreases hepatitis C viral load in overweight, treatment naive, genotype 4 infected-patients: a pilot study. PLoS ONE 7(3), e31516 (2012).
19. Romero-Gómez M, Diago M, Andrade RJ et al.; Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 50(6), 1702-1708 (2009).
20. Serfaty L, Forns X, Goeser T et al. Insulin resistance and response to telaprevir plus peginterferon a and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut 61(10), 1473-1480 (2012).